Inogen, Inc. (NASDAQ: INGN) is a Healthcare company (Medical - Devices) with a market capitalization of $148M. The Maz Rating grades it against the other companies in its sector.
Inogen, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.68, Inogen, Inc. trades at 0.4x sales and 1.0x book value. Over the last twelve months it generated about $339M of revenue and a net loss of $34M. It runs a gross margin of 47.3%, an operating margin of -11.3% and a net margin of -10.5%. It shows return on equity of -20.1%, return on invested capital of -19.2% and a free cash flow yield of -8.6%. On the balance sheet: a debt-to-equity ratio of 0.10 and a current ratio of 2.96. Over the past 52 weeks the share price ranged from $5.04 to $7.67, with a beta of 1.49.
Inogen, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 6 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Inogen, Inc. (INGN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.05% / 30% · (Cash+Inv) / Mkt Cap (36m) 61.0% / 30% · Interest income / Revenue 1.13% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 2.05% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 61.0% / 33% · Receivables / Mkt Cap (36m) 30.6% / 49% · Interest income / Revenue 1.13% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 2.05% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 61.0% / 33.33% · Receivables / Mkt Cap (24m) 30.6% / 33.33% · Interest income / Revenue 1.13% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.59% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 38.2% / 33.33% · Receivables / Avg Assets (4Q) 15.5% / 33.33% · Interest income / Revenue 1.13% / 5% | Fail |
| FTSE | Debt / Total Assets 1.23% / 33.33% · (Cash+ST Inv) / Total Assets 36.6% / 33.33% · (Cash+Recv) / Total Assets 54.9% / 33.33% · Interest income / Revenue 1.13% / 5% | Fail |
No. As of September 2026, Inogen, Inc. (INGN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Inogen, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
About 1.13% of each dividend: Inogen, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.